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Enzymes involved in natural product biosynthesis employ a variety of cofactors, reaction mechanisms, and
substrate preferences to achieve remarkable chemical diversity found in nature. In this issue of Chemistry &
Biology, Goldman and colleagues show how cofactor (FAD) binding affinity impacts the reaction mechanism
and outcome of two related proteins, RebC and StaC, involved in indolocarbazoles biosynthesis.Nature has a unique approach to generate
a large variety of natural products, often
by divergent pathways that are branched
from one common intermediate. Enzymes
that are highly homologous yet differ
sufficiently enough are deployed so that
their corresponding products are chemi-
cally diverse. How these evolutionarily-
related enzymes achieve chemical diver-
sity has been a topic of vigorous pursuits
in the field of natural product biosyn-
thesis. These studies have furthered our
understanding of complex metabolic
pathways and uncovered unusual bio-
logical reactions such as C-H activation
and halogenation (Blasiak and Drennan,
2009). Despite such advances, how these
highly homologous enzymes achieve
chemical diversity remains a mystery
due to a lack of information that correlates
protein structures to their corresponding
regio-specificities.
In this issue of Chemistry & Biology,
using an elegant combination of X-ray
crystallography, structure-based muta-
genesis, and enzymological studies,
Goldman et al. (2012) report how subtle
changes to the molecular scaffold of
an FAD-dependent enzyme alters the
mechanistic role of its flavin cofactor,
which in turn changes the molecular
scaffold of the product. In essence, the
enzymes ‘‘babysit’’ the flavin cofactor to
diversify indolocarbazoles, a large family
of alkaloids with a wide spectrum of bio-
activities that can potentially be applied
as chemo-therapeutics, antibiotics, and
antifungals. Since its discovery 35 years
ago, indolocarbazoles have been found
to inhibit protein kinase, topoisomerase,
and ATP-binding cassette transporter.
Several indolocarbazole compounds arecurrently under clinical trials for treating
cancers (Nakano and Omura, 2009). The
pharmaceutical potential of indolocar-
bazoles spurs interests in their biosyn-
theses (Howard-Jones and Walsh, 2005;
Onaka, 2009; Sa´nchez et al., 2006), and
significant progress has been made in
understanding the biosyntheses of re-
beccamycin (1, Figure 1A) and its close
relative staurosporine (2, Figure 1A) (Asa-
mizu et al., 2011; Groom et al., 2011;
Howard-Jones and Walsh, 2005; Onaka,
2009; Sa´nchez et al., 2006). 1 is an anti-
tumor agent that binds to DNA-topoiso-
merase I complex to prevent replication
of DNA, while 2 is both antitumor and
antifungal that inhibits protein kinases.
Both compounds contain an indolocar-
bazole ring synthesized from two mole-
cules of tryptophan that are coupled by
a tetrameric heme protein to produce
chromopyrrolic acid as the common bio-
synthetic intermediate (3, CPA, Figure 1B).
A cytochrome P450 peroxidase then
catalyzes the intramolecular C-C coupl-
ing and decarboxylation of 3 to form the
indolocarbazole core, which can either
be aryl-aryl-coupled CPA (4) or 7-car-
boxy-K252c (5). Here, the pathways
diverged—for rebeccamycin biosyn-
thesis, the flavoprotein RebC converts 5
to arcyriaflavin A (6, Figure 1B), which
contains the scaffold of rebeccamycin
(1, Figure 1A). In contrast, for staurospor-
ine biosynthesis, the flavoprotein StaC
converts either 4 or 5 to K252c (7,
Figure 1B), the scaffold of staurosporine
(2, Figure 1A). RebC and StaC share a
sequence identity of 65%, and they
mediate distinctly different oxidations
of net 8-electrons and 4-electrons
from CPA, respectively (Figure 1B). TheChemistry & Biology 19, July 27, 2012mystery remains as to how RebC and
StaC, two highly homologous enzymes,
can mediate such different chemical
transformations.
To address this question, in 2007, the
Drennan lab (Ryan et al., 2007) reported
the crystal structure of RebC, which was
found to have a flavoprotein hydroxylase
fold. The pioneering work showed that
RebC has a bound FAD cofactor in an
OUT position (solvent accessible) when
there is no substrate. The FAD is in an
IN position (solvent inaccessible) when
a substrate analog is bound. Subsequent
work further showed that FAD is IN when
reduced (Ryan et al., 2008), suggesting
that the OUT position promotes sub-
strate binding, followed by FAD reduc-
tion in the IN position to protect the
reactive flavin intermediate from solvent.
The FAD is therefore termed ‘‘the mobile
flavin’’. Further, the helix at the putative
substrate entrance, termed ‘‘the melting
helix,’’ becomes ordered when the active
site is occupied. Significantly, when RebC
is soaked with CPA, 7-carboxy-K252c (5)
was trapped in the active site. This ob-
servation supports that 5 is the actual
RebC substrate and offers the critical crys-
tallographic insight about RebC mecha-
nism. Based on this work, Asamizu et al.
(2011) and Groom et al. (2011) showed
that a double mutation in the active site
can interchange the regio-specificities of
RebC and StaC. Still, many questions
remained to be addressed, such as the
identity of StaC substrate and the molec-
ular basis of regio-specificities leading to
the production of 6 versus 7 (Figure 1B).
Now, Goldman et al. (2012) offer an
astute insight addressing these ques-
tions. The FAD binding constants of fourª2012 Elsevier Ltd All rights reserved 787
Figure 1. Rebeccamycin and Staurosporin Structure and Biosynthetic Routes
(A) Rebeccamycin (1) and staurosporine (2).
(B) RebC and StaC, two homologous flavoproteins, babysit the net 8-electron and 4-electron oxidations
from CPA (3), respectively.
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pared by ITC, and the authors found
a correlation between FAD affinity and
the reaction catalyzed, such that a tighter
FAD binding is linked to 8-electron oxida-
tion (such as RebC), as compared to
the weaker FAD binding of 4-electron
oxidation promoted by StaC. Further,
the authors undertook a Hercules effort
of structure-based mutations and pro-
duced a RebC mutant with 10 amino
acid substitutions (termed RebC-10x), as
well as the complementary Stac-10X.788 Chemistry & Biology 19, July 27, 2012 ª2RebC-10x and Stac-10x not only inter-
changed the regio-specificity, but also
the FAD binding affinity. To further probe
substrate binding, the authors then
present the co-crystal structures of
RebC-10x in native, substrate-bound,
and product-bound states, and the
readers are encouraged to enjoy this fine
crystallographic work in its entire details.
Briefly, RebC-10x, which behaves like
StaC, preserves the ‘‘mobile flavin’’ and
‘‘melting helix’’ features. However, the
enzyme-FAD interactions are lessened012 Elsevier Ltd All rights reservedin RebC-10x, resulting in the lowered
FAD affinity. Significantly, when RebC-
10x was soaked with the precursor CPA
(3), a clear density was observed for the
keto-tautomer form of 7-carboxy-K252c
(5), suggesting that RebC and StaC
share the common substrate 5, but in
enol and keto forms respectively. The
enol form in RebC is promoted by right
FAD interactions, while different orienta-
tion of FAD in StaC promotes the keto
form instead. Consequently, the enol
form of 5 is hydroxylated, resulting in
the production of 6 by RebC, whereas
the keto form of 5 resulted in the biosyn-
thesis 7 by StaC (Figure 1B). In essence,
RebC and StaC are babysitting enzymes
that ensure the appropriate reaction
goes forward while preventing unwanted
reactions. The above elucidation of
molecular features that govern the diver-
gent indolocarbazole biosynthesis will
help us understand how natural products
are evolved in nature and will inspire
future work on directing biosynthesis.REFERENCES
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